ProPhase Labs Inc (PRPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProPhase Labs Inc (PRPH) has a cash flow conversion efficiency ratio of -3.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.52 Million) by net assets ($6.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of ProPhase Labs Inc to measure how much of total assets are equity-financed.
ProPhase Labs Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how ProPhase Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ProPhase Labs Inc (PRPH) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
ProPhase Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProPhase Labs Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Altitude Group Plc
LSE:ALT
|
-0.066x |
|
Postmedia Network Canada Corp
TO:PNC-A
|
-0.011x |
|
TEVANO SYSTEMS HLDGS INC.
F:7RBA
|
N/A |
|
Gladstone Land Corporation 6.00% Series C Cumulative Redeemable Preferred Stock
NASDAQ:LANDP
|
0.005x |
|
Northern Bear Plc
LSE:NTBR
|
0.121x |
|
Artisanal Spirits Company PLC
LSE:ART
|
-0.155x |
|
FIH Group PLC
LSE:FIH
|
-0.067x |
|
Kendrick Resources PLC
LSE:KEN
|
-0.071x |
Annual Cash Flow Conversion Efficiency for ProPhase Labs Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of ProPhase Labs Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see ProPhase Labs Inc (PRPH) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.35 Million | $-17.54 Million | -2.385x | -937.94% |
| 2023-12-31 | $49.38 Million | $-11.35 Million | -0.230x | -151.21% |
| 2022-12-31 | $63.63 Million | $28.55 Million | 0.449x | +293.16% |
| 2021-12-31 | $58.63 Million | $-13.62 Million | -0.232x | +5.40% |
| 2020-12-31 | $10.56 Million | $-2.59 Million | -0.246x | -227.91% |
| 2019-12-31 | $11.23 Million | $-841.00K | -0.075x | +41.68% |
| 2018-12-31 | $16.50 Million | $-2.12 Million | -0.128x | -49.70% |
| 2017-12-31 | $33.09 Million | $-2.84 Million | -0.086x | -8.34% |
| 2016-12-31 | $5.96 Million | $-472.00K | -0.079x | +80.01% |
| 2015-12-31 | $8.83 Million | $-3.50 Million | -0.396x | -31.98% |
| 2014-12-31 | $10.72 Million | $-3.22 Million | -0.300x | -432.47% |
| 2013-12-31 | $12.60 Million | $1.14 Million | 0.090x | +118.04% |
| 2012-12-31 | $11.45 Million | $-5.73 Million | -0.500x | -166.43% |
| 2011-12-31 | $11.23 Million | $-2.11 Million | -0.188x | +28.78% |
| 2010-12-31 | $13.46 Million | $-3.55 Million | -0.264x | -933.02% |
| 2009-12-31 | $14.06 Million | $445.00K | 0.032x | +118.40% |
| 2008-12-31 | $17.77 Million | $-3.06 Million | -0.172x | -205.56% |
| 2007-12-31 | $23.30 Million | $-1.31 Million | -0.056x | -250.57% |
| 2006-12-31 | $25.59 Million | $956.94K | 0.037x | -77.76% |
| 2005-12-31 | $25.37 Million | $4.27 Million | 0.168x | -20.79% |
| 2004-12-31 | $21.96 Million | $4.66 Million | 0.212x | +556.59% |
| 2003-12-31 | $20.79 Million | $-966.23K | -0.046x | -257.52% |
| 2002-12-31 | $18.42 Million | $543.64K | 0.030x | +156.01% |
| 2001-12-31 | $21.20 Million | $-1.12 Million | -0.053x | +40.24% |
| 2000-12-31 | $21.21 Million | $-1.87 Million | -0.088x | -277.69% |
| 1999-12-31 | $26.20 Million | $1.30 Million | 0.050x | -75.14% |
| 1998-12-31 | $44.60 Million | $8.90 Million | 0.200x | -7.54% |
| 1997-12-31 | $41.70 Million | $9.00 Million | 0.216x | +123.54% |
| 1996-12-31 | $1.20 Million | $-1.10 Million | -0.917x | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more